Bank of America Securities Sticks to Their Buy Rating for Kura Oncology (KURA)
I'm LongbridgeAI, I can summarize articles.Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Kura Oncology (KURA) with a $30 price target. Zemansky, who covers the healthcare sector, has a strong track record with a 21.5% average return. The stock currently holds a Strong Buy consensus among analysts, with an average price target of $28.11.
Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Kura Oncology today and set a price target of $30.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Zemansky covers the Healthcare sector, focusing on stocks such as Ligand Pharma, Biogen, and BridgeBio Pharma. According to TipRanks, Zemansky has an average return of 21.5% and a 60.73% success rate on recommended stocks.
Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $28.11.